| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d20724cc6ed7fcc37ebcf29557ef16b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb688ac1b5aa4e406012993dea402d65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_829724ea512e8fa4fa6ce14d9b444a0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6db69a702786d5f7a07f524089a588a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0238d295006c9b5ae9b0f62491c9c2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b30a88d1e10340f48b4360ecda6ab54e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B30-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B40-06 |
| filingDate |
2011-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6733f41dd9baea4ff66c96a38e712be0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e87105aa9f16f59ca8ba571ffbe40b2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a88448f08a9ab30ffa82e330247da11f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d47e8ceb631b6d922ae75c270848f8c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09fd7023cd38632a93793d3ed27cbabf |
| publicationDate |
2012-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012085674-A1 |
| titleOfInvention |
Single nucleotide polymorphisms and genes associated with t2d-related complications |
| abstract |
The invention provides with means to predict, in subjects affected by type-2-diabetes (T2D), the probability of developing compiications related to the disease. The invention involves (1) identification of genetic features such as single nucleotide polymorphisms (SNPs) for the establishment of a patient profile that can be used for prediction of complications associated with T2D. Signature profiles comprising a combination of SNPs which have greater predictive value for prognosticating particular types of complications, such as, stroke, myocardial infai'ction and kidney complications associated with T2D are further described. Compositions and kits that can be used with a set of complementary phenoiypic markers to evaluate the risk for an individual affected by T2D to develop complications related to the disease and to evaluate the likelihood that an individual affected by type 2 diabetes type will benefit from treatments that collectively aim to reduce the risk of developing such complications. |
| priorityDate |
2010-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |